» Articles » PMID: 23555904

Impact of Commonly Used Transplant Immunosuppressive Drugs on Human NK Cell Function is Dependent Upon Stimulation Condition

Overview
Journal PLoS One
Date 2013 Apr 5
PMID 23555904
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Lung transplantation is a recognised treatment for patients with end stage pulmonary disease. Transplant recipients receive life-long administration of immunosuppressive drugs that target T cell mediated graft rejection. However little is known of the impact on NK cells, which have the potential to be alloreactive in response to HLA-mismatched ligands on the lung allograft and in doing so, may impact negatively on allograft survival. NK cells from 20 healthy controls were assessed in response to Cyclosporine A, Mycophenolic acid (MPA; active form of Mycophenolate mofetil) and Prednisolone at a range of concentrations. The impact of these clinically used immunosuppressive drugs on cytotoxicity (measured by CD107a expression), IFN-γ production and CFSE proliferation was assessed in response to various stimuli including MHC class-I negative cell lines, IL-2/IL-12 cytokines and PMA/Ionomycin. Treatment with MPA and Prednisolone revealed significantly reduced CD107a expression in response to cell line stimulation. In comparison, addition of MPA and Cyclosporine A displayed reduced CD107a expression and IFN-γ production following PMA/Ionomycin stimulation. Diminished proliferation was observed in response to treatment with each drug. Additional functional inhibitors (LY294002, PD98059, Rottlerin, Rapamycin) were used to elucidate intracellular pathways of NK cell activation in response to stimulation with K562 or PMA-I. CD107a expression was significantly decreased with the addition of PD98059 following K562 stimulation. Similarly, CD107a expression significantly decreased following PMA-I stimulation with the addition of LY294002, PD98059 and Rottlerin. Ten lung transplant patients, not receiving immunosuppressive drugs pre-transplant, were assessed for longitudinal changes post-transplant in relation to the administration of immunosuppressive drugs. Individual patient dynamics revealed different longitudinal patterns of NK cell function post-transplantation. These results provide mechanistic insights into pathways of NK cell activation and show commonly administered transplant immunosuppression agents and clinical rejection/infection events have differential effects on NK cell function that may impact the immune response following lung transplantation.

Citing Articles

Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings.

Poirier N, Paquin V, Leclerc S, Lisi V, Marmolejo C, Affia H J Immunother Cancer. 2024; 12(5).

PMID: 38754915 PMC: 11097815. DOI: 10.1136/jitc-2023-008435.


Influence of immunosuppressive drugs on natural killer cells in therapeutic drug exposure in liver transplantation.

Qin R, Qin J, Li X, Xu Z, He P, Yuan X Hepatobiliary Surg Nutr. 2023; 12(6):835-853.

PMID: 38115918 PMC: 10727815. DOI: 10.21037/hbsn-22-438.


CCR5 drives NK cell-associated airway damage in pulmonary ischemia-reperfusion injury.

Santos J, Wang P, Shemesh A, Liu F, Tsao T, Aguilar O JCI Insight. 2023; 8(21.

PMID: 37788115 PMC: 10721259. DOI: 10.1172/jci.insight.173716.


Cellular activation pathways and interaction networks in vascularized composite allotransplantation.

Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L Front Immunol. 2023; 14:1179355.

PMID: 37266446 PMC: 10230044. DOI: 10.3389/fimmu.2023.1179355.


CD16 natural killer cells in bronchoalveolar lavage are associated with antibody-mediated rejection and chronic lung allograft dysfunction.

Calabrese D, Chong T, Singer J, Rajalingam R, Hays S, Kukreja J Am J Transplant. 2023; 23(1):37-44.

PMID: 36695619 PMC: 10018437. DOI: 10.1016/j.ajt.2022.10.006.


References
1.
Wai L, Fujiki M, Takeda S, Martinez O, Krams S . Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation. 2008; 85(1):145-9. PMC: 4084728. DOI: 10.1097/01.tp.0000296817.28053.7b. View

2.
Warren H . Target-induced natural killer cell loss as a measure of NK cell responses. J Immunol Methods. 2011; 370(1-2):86-92. DOI: 10.1016/j.jim.2011.06.002. View

3.
Hoogduijn M, Roemeling-van Rhijn M, Korevaar S, Engela A, Weimar W, Baan C . Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies. Hum Gene Ther. 2011; 22(12):1587-91. DOI: 10.1089/hum.2011.039. View

4.
Allan J . Immunosuppression for lung transplantation. Semin Thorac Cardiovasc Surg. 2005; 16(4):333-41. DOI: 10.1053/j.semtcvs.2004.09.010. View

5.
Gummert J, Ikonen T, Morris R . Newer immunosuppressive drugs: a review. J Am Soc Nephrol. 1999; 10(6):1366-80. DOI: 10.1681/ASN.V1061366. View